With the principals of the firm - Eleutheria Pharmaceuticals LLC - having ties to Oregon Health and Science University, Portland Oregon,t defined objective of th firm's principals is development of metabotropic glutamate receptor 1 (mGlu1) positive allosteric modulators (PAMs) as therapeutic agents to reduce craving and thereby facilitate abstinence in persons with cocaine use disorder. The target, mGlu1, has been thoroughly validated by the lab of the PI and the firm's founder by other work.
